{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "7751527",
  "DateCompleted": {
    "Year": "1995",
    "Month": "06",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "07",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0091-6749",
      "JournalIssue": {
        "Volume": "95",
        "Issue": "5 Pt 2",
        "PubDate": {
          "Year": "1995",
          "Month": "May"
        }
      },
      "Title": "The Journal of allergy and clinical immunology",
      "ISOAbbreviation": "J Allergy Clin Immunol"
    },
    "ArticleTitle": "Product characteristics and pharmacokinetics of intranasal ipratropium bromide.",
    "Pagination": {
      "StartPage": "1111",
      "EndPage": "1116",
      "MedlinePgn": "1111-6"
    },
    "Abstract": {
      "AbstractText": [
        "The in vivo absorption potential of ipratropium bromide nasal spray was evaluated in studies involving healthy volunteers (0.03%, 0.06%, and 0.12% dosage strengths) and patients with perennial rhinitis (0.03% and 0.06%) and the common cold (0.06%). The dose used was two sprays per nostril, corresponding to a total dose of 84 micrograms, 168 micrograms, and 336 micrograms for the three dosage strengths. These studies indicate that 10% or less of active drug is absorbed systemically after nasal administration based on the amount of unchanged drug excreted in urine in a 24-hour interval. In most instances, the plasma drug concentrations were undetectable. In none of these studies did plasma ipratropium concentrations reach a level where systemic anticholinergic effects are known to occur."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Conn. 06877-0368, USA."
          }
        ],
        "LastName": "Wood",
        "ForeName": "C C",
        "Initials": "CC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Fireman",
        "ForeName": "P",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Grossman",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wecker",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "MacGregor",
        "ForeName": "T",
        "Initials": "T"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Comparative Study",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Allergy Clin Immunol",
    "NlmUniqueID": "1275002",
    "ISSNLinking": "0091-6749"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "GR88G0I6UL",
      "NameOfSubstance": "Ipratropium"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Absorption"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Oral"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cross-Over Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Hemodynamics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Injections, Intravenous"
    },
    {
      "QualifierName": [
        "pharmacokinetics",
        "therapeutic use"
      ],
      "DescriptorName": "Ipratropium"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "drug effects",
        "metabolism"
      ],
      "DescriptorName": "Nasal Mucosa"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Nebulizers and Vaporizers"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Pupil"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism"
      ],
      "DescriptorName": "Rhinitis, Allergic, Perennial"
    }
  ]
}